item management s discussion and analysis of financial condition and results of operations overview in the management discussion and analysis section of the k we are providing more detailed information about our operating results and changes in financial position over the past three years 
this section should be read in conjunction with the consolidated financial statements and related notes beginning on page vivus  inc vivus or the company is the developer and manufacturer of muse r alprostadil and actis r  two advancements in the treatment of men with erectile dysfunction ed  also known as impotence 
the company s objective is to become a global leader in the development and commercialization of innovative therapies for the treatment of sexual dysfunction and urologic disorders in men and women 
vivus has ongoing research and development r d programs in male ed  female sexual dysfunction fsd  and male premature ejaculation pe  and intends to pursue targeted technology acquisitions to expand its r d pipeline 
the company intends to market and sell its products through distribution  co promotion or license agreements with corporate partners 
in december  the company filed a new drug application nda with the us food and drug administration fda for alibra r  its second generation male ed treatment 
in november  the company obtained marketing clearance by the fda to manufacture and market its first product  muse  and commercially introduced muse in the united states beginning in january the launch of muse went on to become one of the top most successful drug launches in the us  and the company recorded a net profit of million and product revenue of million for the year ended december  during  the company experienced a significant decline in market demand for muse as the result of the introduction of a competitor s product in april during the second and third quarters of  the company took significant steps to restructure its operations in an attempt to bring the cost structure in line with current and projected revenues 
as a result  the company recorded a net loss of million for the year ended december  in  the company focused its efforts on building a solid foundation for future growth 
the company achieved profitable quarters throughout and recorded net income of million for the year 
we successfully completed our alibra phase iii clinical trials and filed an nda in the fourth quarter with the fda 
we completed enrollment of our premature ejaculation phase ii proof of concept study  and we have strengthened our financial position  increasing our cash position from million at december  to million at december   while decreasing total liabilities by million during the same period 
the company supports muse sales in the us through physician and patient information help lines  sales support for major accounts  product education newsletters and participation in national urologic and sexual dysfunction forums and conferences  such as the american urological association annual and regional meetings and the international society for impotence research 
in addition  the company supports ongoing research and clinical investigation of muse and the publication of data in peer reviewed journals 
internationally  the company has entered into a licensing and distribution agreement with janssen pharmaceutical janssen for certain international markets  including multiple pacific rim countries excluding japan  canada  mexico  south africa and australia 
the company is seeking a partner s to market and sell its products through distribution  co promotion or license agreements in the united states  europe  japan and south america 
highlights the company was granted a new patent for the treatment of female sexual dysfunction by the us patent office  providing broad patent protection for the commercialization of topical formulations of vasodilating agents and steroid hormones for the treatment of sexual dysfunction affecting women 
the company entered into a binding memorandum of understanding to further solidify its fsd intellectual property position through an exclusive agreement with androsolutions  inc  a privately held biomedical corporation 
definitive agreements were executed in march the company and androsolutions have jointly formed asivi  llc  a delaware limited liability corporation  into which vivus contributed its issued us fsd patent and european application and into which androsolutions has contributed its us and european fsd patent applications 
in turn  asivi has granted the company exclusive global rights to develop and commercialize fsd technologies based on this intellectual property  in return for certain milestone payments and royalties on fsd products developed by vivus 
the company and androsolutions will each own of asivi  llc 
the company intends to account for their interest in asivi  llc 
through the equity method of accounting 
the company began development for its product for the treatment of fsd  alista tm and expects to enter clinical testing during year the company was granted a new patent for the method and composition for treating erectile dysfunction by the us patent office  providing broad patent protection for the commercialization of alibra  its second generation transurethral treatment for male ed 
the company filed an nda for alibra with the fda in the fourth quarter of the company initiated a proof of concept  phase ii clinical study for the evaluation of on demand oral compounds for the treatment of premature ejaculation in men 
the company received million in milestone payments for the approval of muse marketing licenses in france  germany  spain and italy 
the company reached a settlement of the shareholder class action lawsuits 
the settlement for million was funded by insurance proceeds of million and by the company contributing  shares of common stock 
the company terminated its license agreement with albert einstein college of medicine of yeshiva university for the development of gene therapy for the treatment of ed  a strategic decision based on the development risks involved and the amount of funding and time required to potentially bring a product to market 
the marketing and distribution rights in europe  australia  new zealand  central and south america were returned to the company by astrazeneca 
this resulted in the company recording million in revenue in the fourth quarter of  consisting of million in product revenue associated with shipments that occurred throughout and  million in milestone revenue associated with marketing clearance in italy  and million in other revenue 
results of operations years ended december  and product revenues for year ended december  were million in the us and million internationally  compared to million in the us and internationally for the same period in the significant decline in us product revenue is due to lower demand for the company s product muse  which resulted from the launch of sildenafil  a competitive oral treatment for erectile dysfunction 
internationally  revenues decreased to million in  compared to million in the revenue decrease from is mainly attributable to reduced orders from both astrazeneca and janssen 
for the year ended december   the company recorded million in milestone revenue from astrazeneca related to regulatory approvals of muse in france  germany  italy and spain 
for the year ended december   the company recorded million milestone revenue from janssen related to regulatory approvals of muse in south korea and canada 
total revenue in also includes million in other revenue associated with the return of marketing and distribution rights for muse from astrazeneca 
additionally the company recorded a million charge for the actual and anticipated return of expired product in the us these returns are primarily the result of shipments made during the fourth quarter of and first quarter of demand for muse declined following the launch of a competitive product in april  resulting in excess inventories of wholesalers and retailers 
cost of goods sold for the year ended december  were million  compared to million for the same period in the decrease was primarily a result of lower unit shipments in in addition  an inventory valuation reserve of million was recorded in as part of the company s restructuring of its operations 
research and development r d expenses for the year ended december  were million  compared to million in the year ended december  lower spending in was primarily a result of the company s effort to bring overall cost levels in line with the company s projected current and projected revenues 
higher spending in was mainly associated with a significantly larger r d organization 
selling  general and administrative expenses for the year ended december  were million  compared to million in the year ended december  the lower expenses in were primarily a result of the company s effort to bring overall cost levels in line with the company s projected future demand for muse 
included in selling  general and administration expenses for were significant expenses for a direct to consumer advertising campaign as well as a direct sales force  which are not included in operating expenses for the year ended december  include a non cash charge of  for the issuance of  share of common stock toward the settlement of shareholders class action lawsuits 
in addition  the company reclassified million from other restructuring costs during the fourth quarter to allowance for product returns during earlier quarters 
see note on page 
operating expenses for the year ended december  include a restructuring charge of million  primarily associated with the sales force and other personnel reductions  and a million write down of property and equipment 
the write down was calculated in accordance with the provisions of statement of financial accounting standards no 
and represents the excess of the carrying values of property and equipment over the projected future discounted cash flows for the company 
the company recorded a tax provision of five percent of net income before taxes for the effective tax rate calculation includes the effect of nols carried forward from prior periods 
the tax rate would have been substantially higher if the nols were not available to offset current income 
the company had no tax provision for as a result of the loss recorded for this year 
years ended december  and during fiscal  the company took significant steps to restructure its operations in an attempt to bring the cost structure of the business in line with current revenue projections 
these steps included significant reductions in headcount in all departments  as well as the closing of vivus contract manufacturing site located within paco pharmaceutical services  inc  and the consolidation of employees at the company s corporate headquarters into a smaller space within its current building 
as a result  the company recorded million of costs and write downs during fiscal product revenues for year ended december  were million in the us and million internationally  compared to million in the us and million internationally for the same period in the significant decline in us product revenue is due to lower demand for the company s product muse  which resulted from the us launch of sildenafil  a competitive oral treatment for erectile dysfunction 
underlying demand for muse domestically  as measured by retail prescriptions  declined approximately following the commercial launch of sildenafil in april internationally  revenues increased to million in as janssen and astrazeneca were preparing to launch muse in various countries 
for the year ended december   the company recorded million milestone revenue from janssen related to regulatory approvals of muse in south korea and canada 
for the year ended december   the company recorded million milestone revenue  million from janssen for signing the initial and expanded distribution agreements and million from astrazeneca for regulatory approval in the united kingdom 
cost of goods sold for the year ended december  were million  compared to million for the same period in the increase was primarily a result of an inventory valuation reserve of million  primarily related to excess raw materials and future inventory purchase commitments for raw materials in excess of anticipated future demand recorded as a part of the company s restructuring in the third quarter of research and development r d expenses for the year ended december  were million  compared to million in the year ended december  the increase was mainly due to increased spending associated with new product development 
selling  general and administrative expenses for the year ended december  were million  compared to million in the year ended december  the decrease was primarily the result of lower marketing and advertising expenses in addition to personnel reductions in administration  sales and marketing 
during  the company discontinued its direct to consumer advertising  terminated its sales force services agreement with innovex  and agreed to facilitate the transition of its direct sales force to alza corporation 
the company also announced its decision to seek a major pharmaceutical partner to market  distribute and sell muse in the us and its comprehensive effort to reduce expenses 
interest and other income for the year ended december  was million  compared with million for the same period in the decrease was primarily the result of lower average invested cash balances 
liquidity and capital resources since inception  the company has financed operations primarily from the sale of preferred and common stock 
through december   vivus has raised million from financing activities and has an accumulated deficit of million at december  cash  cash equivalents and available for sale securities totaled million at december   compared with million at december  the million increase during was primarily the result of net income of million and collection of accounts receivable of million 
these increases were partially offset by payments made related to the restructuring reserve established in of million 
accounts receivable at december  were million  compared with million at december   a decrease of thousand due primarily to lower sales and improved collections 
total liabilities were million at december   compared with million at december   a decrease of million 
this decrease relates primarily to the payments made related to the restructuring reserve of million and recognition of unearned revenue of million 
these decreases are partially offset by and increase in the reserve for product returns of million 
on october   the company was named in a civil action filed in the superior court of new jersey 
this complaint seeks specific performance and other relief in connection with the company s leased manufacturing facilities located in lakewood  new jersey 
the company s lease agreement requires that the company provide a removal security deposit in the form of cash or a letter of credit 
the company and lessor plaintiff have reached a tentative agreement whereby the company will provide an irrevocable standby letter of credit in the amount of million for such security deposit 
the company believes that current cash  investments  and future cash flows will be sufficient to support the company s operating needs through the company expects that it will be required to issue additional equity or debt securities or use other financing source to fund the development and possible commercial launch of its future products 
this form k contains forward looking statements about future financial results  future products and other events that have not yet occurred 
for example  statements like we expect  we anticipate or we believe are forward looking statements 
investors should be aware that actual results may differ materially from our expressed expectations because of risks and uncertainties about the future 
we will not necessarily update the information in this form k if any forward looking statement later turns out to be inaccurate 
details about risks affecting various aspects of our business are discussed throughout this form k 
investors should read all of these risks carefully  and should pay particular attention to risks affecting the following areas future capital needs and uncertainty of additional financing page  history of losses and limited operating history pages and  limited sales and marketing experience page  dependence on third parties pages and  intense competition page  dependence on key personnel page  and other risk factors as stated pages through 

